Sign in
KANT Stock Price, Chart, Stats & News
Kineta, Inc.
Save
Kineta, Inc. (KANT) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
KANT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -1681.26% |
ROE | 142.40% |
D/E | -0.05x |
Interest coverage ratio | -98.06x |
KANT valuation
P/E | – |
P/S | – |
P/B | – |
P/CF | – |
P/FCF | – |
P/OCF | – |
PEG | – |
EV multiple | – |
About
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers.
Similar securities
Based on sector and market capitalization
Report issue